Tofacitinib citrate 540737-29-9 Rheumatoid arthritis Anticancer
Intlawulo:T/T, L/C
Imvelaphi yeMveliso:eTshayina
Indawo yokuthumela ngenqanawa:Beijing/Shanghai/Hangzhou
Umthamo wemveliso:100kg/ngenyanga
Umyalelo(MOQ):25kg
Ixesha lokukhokhela:Iintsuku zokusebenza ezi-3
Imeko yokugcina:Igcinwe kwindawo epholileyo, eyomileyo, ubushushu begumbi.
Ipakethe imathiriyeli:igubu
Ubungakanani bepakethi:25kg/igubu
Ulwazi ngokhuseleko:Ayizompahla eziyingozi
Intshayelelo
I-Tofacitinib liyeza elisetyenziselwa ukunyanga i-rheumatoid arthritis, psoriatic arthritis, kunye ne-ulcerative colitis.
I-Tofacitinib citrate isetyenziselwa ukuphatha abantu abadala ngokumodareyitha ukuya kwi-rheumatoid arthritis esebenzayo abaye bafumana impendulo engafanelekanga, okanye abangayinyamezeliyo, i-methotrexate.
I-Tofacitinib citrate iboniswa kunyango lwe-arthritis ye-rheumatoid esebenzayo (RA) ephakathi kwabantu abadala abaye basabela ngokufanelekileyo, okanye abangenakunyamezelwa kwi-antirheumatic drug modifying okanye enye okanye ngaphezulu.
Inkcazo (endlwini)
| Into | Inkcazo |
| Imbonakalo | I-crystalline powder emhlophe okanye emhlophe |
| Ukuchongwa | IR, HPLC |
| Amanzi | ≤1.5% |
| Izinto ezinxulumeneyo | TOFA 06 ≤0.15% |
| I-Tofacitinib trans isomer ≤0.15% | |
| I-Tofacitinib dehydrogenated ≤0.15% | |
| Ukungcola ngakunye okungaziwayo ≤0.10% | |
| Ukungcola ngokupheleleyo: ≤1.0% | |
| Izinyibilikisi ezishiyekileyo | I-Ethanol ≤5000ppm |
| I-Benzene ≤2ppm | |
| Toluene ≤890ppm | |
| I-Chlroroethane ≤1000ppm | |
| N, N-Dimethylformamide ≤800ppm | |
| I-Palladium ≤10ppm | |
| IDichloromethane ≤600ppm | |
| Uthuthu lwesulphate | ≤0.1% |
| Intsimbi enzima | ≤10ppm |
| Chrial HPLC | 3S, 4S tofacitinib ≤0.15% |
| Uvavanyo (kwisiseko se-anhydrous) 98.0-102.0% |
